Radioimmunotherapeutic approaches for leukemia: the past, present and future.
For more than a decade, Ab conjugated to a radionuclide emitting particulate radiation has been used in the management of leukemia in an effort to deliver targeted doses of radiation to BM, spleen and other sites of disease, while sparing normal organs. This radioimmunotherapy (RIT) approach has been employed to achieve significant remissions in patients with AML, particularly when used at high doses of radioactivity in conjunction with myeloablation. This report focuses on the therapeutic aspects of radiolabeled Ab for leukemia. Clinical results from recent leukemia RIT studies are reviewed, with emphasis on approaches being evaluated to improve rates of response and survival. Discussion of pre-clinical studies are limited to those that offer insights into future directions for clinical RIT studies of leukemia.
Pagel
J M
JM
Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, Washington 98109, USA. jpagel@fhcrc.org
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007938:Leukemia / Q000532:radiotherapy*; D008954:Models, Biological; D016499:Radioimmunotherapy / Q000379:methods* / Q000639:trends
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes